However, due to the pleiotropic activity of TRPA1 and TRPV4, the safety profile of channel antagonism should be carefully scrutinized, particularly regarding the impact of this therapeutic strategy on cancer outcome and on the efficacy of cancer treatment. The gene discussed is TRPV4; the disease is cancer.